Q-omics provides the consensus-scored UBL3 profile across patient tissues and cancer cell-line models. UBL3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, UBL3 is differentially expressed in 12, with the highest sampling consensus in HNSC. Additionally, UBL3 RNA expression shows 21,057 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, HNSC, and THYM as cancer lineages where UBL3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UBL3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UBL3 survival associations across molecular data types. UBL3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UBL3 RNA expression–survival associations across cancer types. High UBL3 expression shows unfavorable associations in CESC, STAD and UVM, but favorable associations in KIRC, LGG and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for UBL3 RNA expression.
This table summarizes UBL3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 7. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for UBL3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UBL3 shows lower tumor expression in HNSC, LUAD, UCEC, KIRC, LUSC and STAD. The HNSC box plot shows higher UBL3 RNA expression in normal versus tumor tissue (log2 FC = −1.044, t-test p < 0.001).
This table shows molecular features associated with UBL3 in patient tissues and cancer cell lines. In patient samples, UBL3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UBL3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in KIDNEY and BLOOD_Leukemia.
